Harness Therapeutics appoints Leading World Experts in Neurodegenerative Diseases to its Scientific Advisory Board (SAB)
30 mai 2024 07h00 HE | Harness Therapeutics
Newly established SAB of prominent geneticists, biologists and Huntington’s disease specialists’ marks pivotal step in accelerating progress of lead programme HRN001 Cambridge, UK, May 30, 2024:...
Harness Therapeutics Appoints Seasoned Biopharmaceutical Leader, Ms. Meenu Chhabra Karson, as Board Chair
24 avr. 2024 03h00 HE | Harness Therapeutics
Ms. Chhabra Karson brings highly successful 20-year track record in industry leadership roles Cambridge, UK, April 24 2024: Harness Therapeutics, a biotechnology company focused on protein...
Harness Therapeutics secures additional £4 million funding to pursue physiological upregulation approach to treat neurodegenerative diseases
28 nov. 2023 04h00 HE | Harness Therapeutics
Harness, formerly operating as Transine, broadens its approach to physiological protein upregulation through post-transcriptional modulation of protein synthesisRefined focus on neurodegenerative...